Calton & Associates’s Intersect ENT, Inc XENT Stock Holding History

Calton & Associates’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,000	Closed	-$35K	–	1378
2017 Q4	$35K	Buy	+1,000	New	+$30K	0.01%	772

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Calton & Associates's XENT Position: Q1 2018 in Review

Calton & Associates sold out of Intersect ENT, Inc (XENT) in Q1 2018, closing a stake of 1,000 shares — an estimated $35K sold.

Calton & Associates first reported a position in XENT in Q4 2017 and held it in 1 quarter. The position peaked at $35K in Q4 2017. 172 funds tracked by Wall St. Rank hold XENT as of Q1 2018.

Calton & Associates reported no remaining Intersect ENT, Inc position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 1,000 Intersect ENT, Inc shares in Q1 2018, an estimated $35K.
Calton & Associates first reported a position in Intersect ENT, Inc in Q4 2017 and held it in 1 quarter.
Calton & Associates's Intersect ENT, Inc position peaked at $35K in Q4 2017.
172 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.